PHARMACOKINETICS - MINUTES IN PLASMA
DSIP Half Life and Pharmacokinetics
Cleared from the blood in minutes, moved into the brain by a specific saturable carrier, and never characterized in a validated human profile. The kinetics that shape every DSIP study.
The short version
DSIP half life is the single most practical fact about this peptide: in animals, it disappears from the bloodstream within minutes. An enzyme-immunoassay study in dogs, monkeys, and rats measured plasma half-lives on the order of only a few minutes, the result of fast breakdown by the body's enzymes [10]. (Half-life just means the time for half of a dose to clear; a few minutes is very short.) That single number explains a lot: why studies gave DSIP by injection rather than as a pill, why a swallowed version does not really work, and why so much recent effort goes into building more stable versions. Two things to note honestly: there is no validated human half-life for DSIP at all, and despite clearing so fast, some people report effects lasting much longer, a mismatch the science has not fully explained. This page covers how DSIP is cleared and, just as important, how it gets into the brain in the first place.
How fast DSIP is cleared
The core pharmacokinetic finding comes from a purpose-built enzyme immunoassay used to measure DSIP's metabolic clearance rate after intravenous dosing in dogs, with comparison across species: the plasma half-life was on the order of only a few minutes, species-dependent, attributed to rapid degradation by aminopeptidases and plasma proteins [10]. The breakdown is specific, not random; in rat brain homogenate, DSIP was degraded with release of its N-terminal tryptophan (about 30% released after 7.5 minutes), with an optimal degradation pH of 7.35, and neither morphine nor REM-sleep deprivation altered the rate [11]. Fast, enzyme-driven, and consistent, the picture is of a molecule the body dismantles quickly and deliberately.
Crossing the blood-brain barrier
A peptide that vanishes from the blood in minutes still has to reach the brain to affect sleep, and DSIP does so by a real, specific mechanism, the lens this whole site is built around. In the vascularly perfused guinea-pig brain, DSIP crossed the blood-brain barrier through a saturable, high-affinity transport system, competitively inhibited by L-tryptophan, evidence of specific carrier binding sites on the capillary membrane rather than passive diffusion [8]. 'Saturable' means the carrier has a finite capacity: once its transporters are busy, the crossing rate maxes out, the fingerprint of a specific mechanism. A dog study built on this by showing that a three-factor model, plasma level times half-life times lipophilicity, predicted entry into the cerebrospinal fluid, giving a rational target for designing analogs that reach the brain better [9].
Why the kinetics drive everything else
Put the two facts together, minutes-long clearance and a finite-capacity brain carrier, and DSIP's whole research arc makes sense. The short half-life is why the field keeps returning to more stable analogs and engineered delivery: the phosphorylated form DSIP-P and other analogs are reported as more stable or potent [17], and a 2024 fusion peptide built specifically to cross the blood-brain barrier (DSIP-CBBBP) reduced wakefulness by about 31% in a chemically induced insomnia mouse model, outperforming native DSIP [6]. The broader principle, that peptides cross the barrier in both directions through dynamic, saturable transporters that themselves change with development and physiology, is the frame a 2015 review uses to explain how peptide drugs might be routed to the brain at all [14]. The honest gap remains the human one: there is no validated human pharmacokinetic profile for DSIP, so the animal half-life is the best available number, not a confirmed human value [3].